Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
27 pending office actions • 16 art units • 27 examiners • 0 of 27 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
Trustees of Tufts College maintains a portfolio with 25 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 25 distinct examiners, indicating that pending matters are currently being reviewed by different individuals. This distribution is further reflected in the involvement of 15 distinct art units, showing technical variety. The high number of examiners ensures that the outcome of the portfolio does not depend on any single individual.
The busiest examiner, MULVANEY, ELIZABETH EVANS, is responsible for 1 busiest examiner pending action. Given that the total workload consists of the 25 pending office actions, the prosecution effort is decentralized. The presence of 15 distinct art units suggests a range of technical subject matter within the Biotechnology & Pharmaceuticals sector, requiring varied strategies across different examination groups. Practitioners must manage many examiner personalities and art unit policies to navigate this volume of active cases. This diversity requires a robust management approach to ensure consistency across the various filings.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (15%) |
| §102 only | 1 (4%) |
| §112 only | 3 (11%) |
| Double-patenting + other | 5 (19%) |
| Multi-statute (no §101) | 14 (52%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| MULVANEY, ELIZABETH EVANS | 1 | 78.9% | +15.1% |
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| DEVI, SARVAMANGALA | 1 | 65.3% | +55.3% |
| ROBERTS, ANNA L | 1 | 56.7% | +38.5% |
| BROPHY, MATTHEW J | 1 | 68.5% | +34.3% |
| ALLEY, GENEVIEVE S | 1 | 60.3% | +48.2% |
| BASS, DIRK R | 1 | 62.4% | +22.8% |
| LEE, RIP A | 1 | 83.5% | -4.2% |
| LIPPERT, JOHN WILLIAM | 1 | 58.2% | +40.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274010 | Thread-Based Transistors | KIELIN, ERIK J | 155d overdue |
| 18360217 | RAPID HIGH THROUGHPUT SCREENING SYSTEM TO ASSESS POTENTIAL TREATMENTS FOR SPORADIC ALZHEIMER’S DISEASE | MARVICH, MARIA | 87d overdue |
| 17778482 | DIRECTED CHANGES IN ORGANISM POPULATIONS | PENNINGTON, KATIE LEIGH | 17d overdue |
| 18342271 | SILK-BASED ARTICLES HAVING DECREASED WATER UPTAKE AND IMPROVED MECHANICAL PROPERTIES, AND METHODS OF MAKING AND USING THE SAME | JOHNSON, JENNA LEIGH | 15d |
| 18034225 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | PETERS, ALEC JON | 34d |
| 18033492 | ENHANCED HYT-INDUCED PROTEIN DEGRADATION USING LIPID NANOPARTICLE DELIVERY | ARMATO JR, DENNIS IGNATIUS | 41d |
| 19292322 | ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOF | OUSPENSKI, ILIA I | — |
| 18966464 | MICROPATTERNED SILK-DOPAMINE ADHESIVES COMPOSITE | MULVANEY, ELIZABETH EVANS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19292322 | ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOF | OUSPENSKI, ILIA I | — |
| 18966464 | MICROPATTERNED SILK-DOPAMINE ADHESIVES COMPOSITE | MULVANEY, ELIZABETH EVANS | — |
| 18845749 | LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA | SONG, JIANFENG | — |
| 18804673 | METHODS, COMPOSITIONS AND KITS FOR TREATING A SUBJECT USING A RECOMBINANT HETEROMULTIMERIC NEUTRALIZING BINDING PROTEIN | DEVI, SARVAMANGALA | — |
| 18834377 | Ingestible Capsule with Beads for Sampling Content of the Gastrointestinal Tract | ROBERTS, ANNA L | — |
| 18766092 | FIXED FUNCTION SHARED ACCELERATOR | BROPHY, MATTHEW J | — |
| 18746604 | SILK-BASED ARTICLES HAVING VARIABLE ACTIVE AGENT RELEASE RATES | ALLEY, GENEVIEVE S | — |
| 18705119 | ARTICLES AND METHODS FOR PLASMA SEPARATION | BASS, DIRK R | — |
| Art Unit | Apps |
|---|---|
| 1613 | 2 |
| 1645 | 2 |
| 1631 | 2 |
| 1618 | 2 |
| 1634 | 2 |
| 3791 | 2 |
| 1644 | 1 |
| 1617 | 1 |
| 2814 | 1 |
| 1789 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19292322 | ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | §103§112 | Final Rejection | — | Pending | Aug 06, 2025 |
| 18966464 | MICROPATTERNED SILK-DOPAMINE ADHESIVES COMPOSITE | MULVANEY, ELIZABETH EVANS | — | §103§112 | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18845749 | LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA | SONG, JIANFENG | 1613 | §102DP | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18804673 | METHODS, COMPOSITIONS AND KITS FOR TREATING A SUBJECT USING A RECOMBINANT HETEROMULTIMERIC NEUTRALIZING BINDING PROTEIN | DEVI, SARVAMANGALA | 1645 | §102§112DP | Non-Final OA | — | Pending | Aug 14, 2024 |
| 18834377 | Ingestible Capsule with Beads for Sampling Content of the Gastrointestinal Tract | ROBERTS, ANNA L | 1613 | §102§103§112 | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18766092 | FIXED FUNCTION SHARED ACCELERATOR | BROPHY, MATTHEW J | — | §103 | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18746604 | SILK-BASED ARTICLES HAVING VARIABLE ACTIVE AGENT RELEASE RATES | ALLEY, GENEVIEVE S | 1617 | §112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18705119 | ARTICLES AND METHODS FOR PLASMA SEPARATION | BASS, DIRK R | — | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18684986 | AMPHIPHILIC POLYAMPHOLYTES AND RELATED MEMBRANES | LEE, RIP A | — | §102§112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18683663 | RADIOFLUORINATED AGENTS FOR PET IMAGING SELECTIVELY TARGETING FIBROBLAST ACTIVATION PROTEIN | LIPPERT, JOHN WILLIAM | — | §103 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18294033 | CULTURED ADIPOSE TISSUE | GRABER, JAMES J | 1631 | §102§103 | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18283391 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | DONOHUE, SEAN R | 1618 | §103§112DP | Final Rejection | — | Pending | Sep 21, 2023 |
| 18360217 | RAPID HIGH THROUGHPUT SCREENING SYSTEM TO ASSESS POTENTIAL TREATMENTS FOR SPORADIC ALZHEIMER’S DISEASE | MARVICH, MARIA | 1634 | §102§112Other | Final Rejection | 87d overdue | Pending | Jul 27, 2023 |
| 18274010 | Thread-Based Transistors | KIELIN, ERIK J | 2814 | §102§103 | Non-Final OA | 155d overdue | Pending | Jul 25, 2023 |
| 18342271 | SILK-BASED ARTICLES HAVING DECREASED WATER UPTAKE AND IMPROVED MECHANICAL PROPERTIES, AND METHODS OF MAKING AND USING THE SAME | JOHNSON, JENNA LEIGH | 1789 | §102§103§112 | Final Rejection | 15d | Pending | Jun 27, 2023 |
| 18265561 | LIPIDOID COMPOSITIONS AND METHODS OF USE THEREOF | KAMM, JUDITH MARIE | 1637 | §103§112DP | Non-Final OA | — | Pending | Jun 06, 2023 |
| 18205096 | LIPID-LIKE NANOCOMPLEXES AND USES THEREOF | ANTHOPOLOS, PETER | 1611 | §103Other | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18254929 | ENGINEERED MULTICELLULAR ORGANISMS | KIM, TAEYOON | 1631 | §102§103§112 | Non-Final OA | — | Pending | May 30, 2023 |
| 18037430 | Spatially-Selective Sampling of Gut Microbiome | YOON, CHANEL J | 3791 | §102§103§112 | Non-Final OA | — | Pending | May 17, 2023 |
| 18034225 | FAP-ACTIVATED SERUM EXTENDED HALF-LIFE THERAPEUTIC CONJUGATES | PETERS, ALEC JON | 1641 | §103§112Other | Final Rejection | 34d | Pending | Apr 27, 2023 |
| 18033492 | ENHANCED HYT-INDUCED PROTEIN DEGRADATION USING LIPID NANOPARTICLE DELIVERY | ARMATO JR, DENNIS IGNATIUS | 1651 | §103§112 | Non-Final OA | 41d | Pending | Apr 24, 2023 |
| 18162137 | ANTIPHOSPHOLIPID ANTIBODIES FOR THE DIAGNOSIS OF LYME DISEASE | MORGAN, BAILEY MICHELLE | 1645 | §112 | Final Rejection | — | Pending | Jan 31, 2023 |
| 17904690 | METHODS FOR ENGINEERING AMINO ACID AMMONIA LYASE ENZYMES AND ENZYMES THEREBY OBTAINED | IANNUZO, NATALIE NMN | 1653 | §103 | Final Rejection | 19d | Pending | Aug 19, 2022 |
| 17838891 | SYNTHETIC LIPID-LIKE MATERIALS FOR BRAIN DELIVERY | DAVIS, BRIAN J | 1614 | §102 | Non-Final OA | 24d overdue | Pending | Jun 13, 2022 |
| 17778482 | DIRECTED CHANGES IN ORGANISM POPULATIONS | PENNINGTON, KATIE LEIGH | 1634 | §102§103§112Other | Non-Final OA | 17d overdue | Pending | May 20, 2022 |
| 17753312 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT SCREENING AND ANALYSIS OF DRUG DELIVERY SYSTEMS IN VITRO | WESTERBERG, NISSA M | 1618 | §103§112DP | Final Rejection | 19d overdue | Pending | Feb 28, 2022 |
| 16979957 | Acquisition of Samples for Evaluating Bacterial Demographics | BLOCH, MICHAEL RYAN | 3791 | §112 | Final Rejection | 36d overdue | Pending | Sep 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial